Reviewer's report

Title: Maternal Safety of the Delayed-Release Doxylamine and Pyridoxine Combination for Nausea and Vomiting of Pregnancy; A Randomized Placebo Controlled Trial

Version: 3  Date: 20 October 2014

Reviewer: Anne Matthews

Reviewer's report:

An excellent paper overall, very clearly written and will add to this field; discussion of results linked to BMI and dose is welcome.

Discretionary Revisions

page 3(2nd paragraph in background): Can it be conclusively stated ('in fact') that the withdrawal of Bendectin 'was associated' with a two-fold increase in rate of hospitalisation for HG- in other words that untreated NVP leads to HG- are they not substantively different- perhaps at least outline and examine the claims of the references used to support this point- (refs 6-7).

Throughout- while it is understandable the Diclegis(r) is used to identify the brand/drug used, is it feasible/preferable to use the 'doxylamine succinate & pyridoxine hydrochloride' generic name in place of the drug name? It the brand name is used, it is useful that it is made clear that it has the same composition as Diclectin and Bendectin (end page 3).

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, and I have assessed the statistics in my report.

Declaration of competing interests:

I declare that I have no competing interests.